Home / Pharma News

Pharma News

Biocon partners with Libbs for the sale of generics in Brazil

India-based biologicals specialist Biocon has formed an out-licensing agreement with Brazil-based company Libbs Farmaceutica for the sale of generic drugs in the country, marking Biocon’s entry into the Latin American market for generics. 

India-based biologicals specialist Biocon has formed an out-licensing agreement with Brazil-based company Libbs for the sale of generic drugs in the country, marking Biocon’s entry into the Latin American market for generics.

New partnerships for Cipla and Samsung Bioepis

In March 2021, Cipla announced that its subsidiary, Cipla Gulf is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. Samsung Bioepis also announced that it has signed a marketing partnership with Yuhan to launch its biosimilar of Humira (adalimumab), Adalloce, in South Korea.

Pfizer sells Chinese copy biologicals plant to WuXi Biologics

China-based WuXi Biologics announced on 17 March 2021 that it had made an agreement with Pfizer China to acquire its state-of-the-art biologicals manufacturing facilities as well as its labour force in Hangzhou, China.

Sandoz acquires GSK antibiotics and Perrigo generics sold to Altaris

In February 2021, Sandoz signed an agreement to acquire GSK’s cephalosporin antibiotics business. In March 2021, Perrigo Company sold their generic drug business to private investment firm, Altaris Capital Partners LLC. 

Biocon Biologics partners to improve global access to cancer treatments and insulin

In February 2021, Biocon Biologics joined forces with international organizations to improve access to cancer and diabetes treatments. The India-based biological subsidiary of Biocon, entered into an agreement with the Clinton Health Access Initiative (CHAI) to expand access to cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP) [1]. In addition, they have become the first biosimilar insulin company to partner with the International Diabetes Federation (IDF) to promote and support the latter’s initiatives [2].

Korean biosimilars makers pipelines and expansion

Korean biosimilars makers have started conducting global clinical trials and are expanding into other markets with their biosimilars.

Innovent makes deal for bevacizumab copy biological in Indonesia

China-based Innovent Biologics (Innovent) announced on 19 January 2021 that it had made an agreement with PT Etana Biotechnologies Indonesia (Etana) to out-license the development and commercialization rights for its bevacizumab copy biological, Byvasda, in Indonesia to Etana.

Partnerships formed and extended between Isu Abxis/Pharmasyntez and Alvotech/Fuji Pharma

The South Korean company Isu Abxis will export technology for a rare blood disease treatment, a biosimilar of Soliris, to the Russian firm Pharmasyntez.

Top 10 most read GaBI Online articles in 2020

This article reviews some of the most important events for biosimilars during 2020. For biosimilars these included the World Health Organization’s (WHO) prequalification of its first biosimilar and US Food and Drug Administration (FDA) rules and guidance. Other subjects of interest for biosimilars were European Medicines Agency (EMA) approvals, the biosimilars market in Latin America, biosimilar litigation, and extrapolation, immunogenicity, switching and substitution of biosimilars.

Celltrion: Takeda acquisitions and new plant development

Celltrion completed the acquisition of selected primary care assets from Takeda Pharmaceutical Company Limited in the Asia Pacific region in November 2020. In addition, the company announced it will be building a new biopharmaceutical plant and a global biotechnology research centre in Songdo, Incheon, South Korea.